FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis

Liwei Lang1†, Yuanping Xiong1,2†, Nestor Prieto-Dominguez3, Reid Loveless1, Caleb Jensen1, Chloe Shay3 and Yong Teng1,4,5*

Abstract

Background: There is no consensus about the effective dosages of melatonin in cancer management, thus, it is imperative to fully understand the dose-dependent responsiveness of cancer cells to melatonin and the underlying mechanisms.

Methods: Head and neck squamous cell carcinoma (HNSCC) cells with or without melatonin treatment were used as a research platform. Gene depletion was achieved by short hairpin RNA, small interfering RNA, and CRISPR/Cas9. Molecular changes and regulations were assessed by Western blotting, quantitative RT-PCR (qRT-PCR), immunohistochemistry, and chromatin Immunoprecipitation coupled with qPCR (ChIP-qPCR). The therapeutic efficacy of FGF19/FGFR4 inhibition in melatonin-mediated tumor growth and metastasis was evaluated in orthotopic tongue tumor mice.

Results: The effect of melatonin on controlling cell motility and metastasis varies in HNSCC cells, which is dose-dependent. Mechanistically, high-dose melatonin facilitates the upregulation of FGF19 expression through activating endoplasmic stress (ER)-associated protein kinase RNA-like endoplasmic reticulum kinase (PERK)-Eukaryotic initiation factor 2 alpha (eIF2α)-activating transcription factor 4 (ATF4) pathway, which in turn promotes FGFR4-Vimentin invasive signaling and attenuates the role of melatonin in repressing metastasis. Intriguingly, following long-term exposure to high-dose melatonin, epithelial HNSCC cells revert the process towards mesenchymal transition and turn more aggressive, which is enabled by FGF19/FGFR4 upregulation and alleviated by genetic depletion of the FGF19 and FGFR4 genes or the treatment of FGFR4 inhibitor H3B-6527.

Conclusions: Our study gains novel mechanistic insights into melatonin-mediated modulation of FGF19/FGFR4 signaling in HNSCC, demonstrating that activating this molecular node confines the role of melatonin in suppressing metastasis and even triggers the switch of its function from anti-metastasis to metastasis promotion. The blockade of FGF19/FGFR4 signaling would have great potential in improving the efficacy of melatonin supplements in cancer treatment.

Keywords: FGF19/FGFR4 axis, Melatonin, ER stress, Metastases, H3B-6527, HNSCC
Background

Fibroblast growth factors (FGFs) are a family of 22 different proteins that bind and stimulate a specific group of tyrosine kinase receptors called FGFRs. FGF19 is a non-canonical FGF that can control a broad spectrum of physiological and pathological responses by signaling through its receptor FGFR4 [1–3]. FGF19 was first characterized in hepatocellular carcinoma (HCC) as an oncogenic driver [4, 5]. Previous studies in our laboratory have revealed that FGF19 directly activates FGFR4-GSK3β signaling cascade in HCC cells to promote the epithelial-mesenchymal transition (EMT) by upregulating β-catenin pathway and provide a cytoprotective role against endoplasmic reticulum (ER) stress by promoting Nrf2 pathway [6, 7]. We further demonstrated that inhibition of FGF19 not only suppresses HCC metastasis but also increases its sensitivity to sorafenib by enhancing reactive oxygen species (ROS)-associated apoptosis [8].

Melatonin (MT) is a methoxyindole synthesized and released by the pineal gland and other extrapineal sources, including the oral cavity and the salivary glands [9–11]. There is highly credible evidence outlining the relevance of MT to human physiology and pathology. Although MT principally functions to control sleep-wake, circadian, and seasoning cycles, it also carries out anti-inflammatory, antioxidant, and immunomodulatory actions in different human tissues [9, 10, 12–16]. As to cancer, MT exhibits oncostatic features mitigating cancer at the initiation, progression, and metastasis phases through receptor-dependent and/or -independent mechanisms [13–15, 17–20]. Moreover, induction of apoptosis and endoplasmic reticulum (ER) stress contribute to the beneficial effects of MT in cancer treatment. There are five groups of molecules interfering with ER stress, including drugs directly interacting with the ER signaling, chemical chaperones, protein degradation inhibitors, drugs affecting calcium signaling, and antioxidants [21, 22]. One of the mechanisms of the action of MT is that it functions as a potent antioxidant and free radical scavenger exhibiting sensitizing effects on ER stress-induced apoptosis in cancer cells [21]. Importantly, MT has shown to be an endogenously generated agent helpful in cancer prevention and treatment due to its low toxicity [15, 16]. A good example is that MT can be used as a potential adjuvant treatment in oral cancer therapy [11]. Although most experts advise to avoid extremely high dosages of MT, there is no consensus about its effective dose in cancer management [23, 24]. In order for the better use of MT in the clinic, there is an urgent need for fully understanding the dose-dependent responsiveness of cancer cells to MT and the underlying mechanisms.

Methods

Cell lines and culture

HNSCC cell lines HN6, HN12, and HN30 were a gift from Dr. W. Andrew Yeudall and maintained in our lab [25, 27]. Human telomerase-immortalized tonsillar keratinocytes hTERT HAK Clone 41 were a gift from Dr. A. Klingelhutz and Dr. J. Lee (University of Iowa, Iowa City, IA) and cultured in KSFM with 0.2 ng/ml EGF and 30 μg/ml bovine pituitary extract [28]. All cells were used for experiments before passage 10 and cultured in DMEM containing 10% fetal bovine serum at 37 °C in a humified incubator supplied with 5% CO₂. Luciferase stable HN30 cells were generated by transduction of pGL4.5 vector (Promega, Madison, WI) and selection of hygromycin for 6 weeks. MT long-term exposure (MT-LE) HN30 cells were generated by exposure to 5 mM MT and maintenance in the medium containing the same dose of MT for more than 10 generations.

Constructs, reagents, antibodies and standard assays

MT, D-luciferin bioluminescent substrate, alamarBlue Cell Viability Reagent, and Dead Cell Apoptosis Kit were purchased from ThermoFisher Scientific (Waltham, MA). MT stock solution at 1 M was prepared by dissolving it in DMSO in ultrasonic sonication bath. For in vivo assays, MT was dissolved in 20% glycofurol solutions to reduce the potential toxicity to mice. The full-length FGF19 gene was amplified from HN30 cells and cloned into pcDNA3.1 (+) expression vector (Invitrogen, USA) as previously described [7]. FGFR4-specific inhibitor H3B-6527 was purchased from Selleckchem (Houston, TX). Antibodies that recognize ATF4, PERK, p-PERK, IRE-1, eIF2α, p-eIF2α, E-cadherin, Vimentin, Puma, Noxa, Bcl-2, and Bax were purchased from Cell Signaling Technology (Beverly, MA). Antibodies against FGF19, FGFR4, p-FGFR4 and β-Actin were obtained.

Little progress has been made in the treatment of head and neck squamous cell carcinoma (HNSCC) in decades due to the lack of impactful targeted therapies [25, 26]. We have demonstrated that blockade of tumor-derived FGF19/FGFR4 signaling represents a promoting therapeutic strategy to preferentially target FGF19-driven HNSCC [25]. Here, we report for the first time that MT has the ability to induce ER stress-associated FGF19 up-regulation in a dose-dependent fashion, which in turn activates FGFR4-Vimentin invasive signaling in HNSCC cells. We also unveil the previously unrecognized influence of FGF19/FGFR signaling on the role of MT in metastasis. Results obtained demonstrate the impact of MT dosages on HNSCC malignancy, suggesting inhibition of FGF19-FGFR signaling axis to be a potential strategy for improving the therapeutic efficacy of MT supplements.
from Abcam (Cambridge, MA). Western blotting, RT-PCR, wound healing assays, Annexin V FITC/PI double staining, and cell viability assays were carried out as we described previously [1, 7, 25, 27, 29]. Proteins were visualized using a SuperSignal West Pico chemiluminescence kit (Pierce) and quantified with ImageJ Fiji (version 1.2; WS Rasband, National Institute of Health, Bethesda, MD).

Quantitative RT-PCR (qRT-PCR) and chromatin immunoprecipitation qPCR (Chip-qPCR)

Total RNA was isolated from cells or tissue using Trizol (Invitrogen, San Diego, CA) according to the manufacturer’s instructions. QRT-PCR analysis was conducted with Applied Biosystems™ Power SYBR™ Green PCR Master Mix (ThermoFisher Scientific) using the StepOne Plus Real Time PCR System (Applied Biosystems, Foster City, CA). Gene expression levels were normalized against β-actin. In this assay, primers for human FGFR19 were: 5′-GGAGATCCCGCCAGATGCTAC-3′ (Forward) and 5′-GGGCCCTAGTCCGGTTGGAACACG-3′ (Reverse). Primers for human β-actin were: 5′-GAGCACAGAGGCTCCGCTTT-3′ (Forward) and 5′-CTCATCATCCTGAGCTTG-3′ (Reverse). ChiP assay were performed using the anti-ATF4 antibody (Abcam) and the ChiP Assay Kit (Millipore, Burlington, MA) as described previously [7]. Normal rabbit IgG-AC (Santa Cruz Biotechnology, Dallas, TX) was used as a negative control for the antibody. The immunoprecipitated genomic DNA was amplified by qPCR using the PCR primers (Forward: 5′-ACTCCACTTTCTCCTGGAATC-3′; Reverse: 5′-TCCCCCTCTCTTCACCCGC-3′) designed to amplify a proximal promoter region containing the putative ATF4 binding element AARE (5′-CTTGATGCA-3′) on the FGFR19 promoter.

Constructs and gene modifications

The pLKO.1-puro TRC non-targeting short hairpin RNA (shRNA) control (shCTRL) and shRNAs targeting FGFR19 (shFGFR19-1, shFGFR19-2) were obtained from Horizon Discovery (Waterbeach, UK). Lentiviruses were packaged in 293FT cells with an optimized mix of the three packaging plasmids (pLP1, pLP2, and pLP/VSVG) using the ViraPower™ Lentiviral Expression System (Invitrogen). Parental HN30 cells with or without FGF19 knockdown were individually injected into anterior ~1/3 tongue of NSG mice under anesthesia. DMSO or MT (2.5 mM and 5 mM) was intratumorally injected when the tongue xenografts reached ~50 mm³, and the xenografts were harvested for western blotting and immunohistochemistry (IHC) after 12 h. To assess the effect of FGFR19 loss, 2 × 10³ HN12 cells were suspended in 50 µl of PBS/Matrigel (3:1) and injected into anterior ~1/3 tongue of NSG mice under anesthesia. DMSO or MT was delivered every 3 days for 2 weeks. Tumor growth and metastasis were measured externally every week by bioluminescence measurement using a Xenogen IVIS-200 In Vivo Imaging System (PerkinElmer, Waltham, MA). Images were quantified as photons/second using the Living Image software. The mice were sacrificed at the endpoint, and the primary xenografts and the major organs were then removed for H&E staining and IHC analysis.

Assessment of FGFR19 and MT in HNSCC patients

The present studies in human biological specimens were reviewed and approved by the Institutional Review Board of the First Affiliated Hospital of Nanchang University, China. All samples were obtained with informed consent. The blood samples from thirty-five adult patients who...
have HNSCC with median age 58 years old were collected from the antecubital vein between 6:00 am and 8:00 am 1 day before surgery. The blood samples in the control group were from ten healthy age-matched people. Within 1 hour after collection, the blood samples were placed immediately on ice until centrifugal sera separation and storage at −80°C. The Melatonin ELISA Kit (BioVision, Milpitas, CA) and the Human FGF19 Quantikine® ELISA kit (R&D Systems, Minneapolis, MN) were used for quantitative measurement of MT and FGF19 in blood samples. Tumor tissues from the same cohort of HNSCC patients were collected for IHC to assess FGF19 levels. The clinicopathologic characteristics of sample sets was shown in Supplementary Table S1.

IHC
IHC was performed as we previously described [25, 33, 34]. Briefly, Paraffin-embedded xenografts or tissues were cut into 3 μm sections and mounted on slides, followed by blocking in 10% of normal goat serum after antigen retrieval in hot citrate buffer. The sections were then incubated with the primary antibodies against FGF19 or Vimentin. Consecutive sections were stained with hematoxylin to help localize cancer tissues and adjacent normal epithelium, and immuno-reactivity was visualized and analyzed using the DAB Kit (Vector Laboratories, Burlingame, CA) under a CCD camera (Olympus, Center Valley, PA). Samples were examined by three investigators who were blind to pathological information. At least ten random microscopic fields were captured per sample, and signal intensity was then semi-quantified using ImageJ Fiji (version 1.2) as described previously [35].

Statistical analysis
All in vitro experiments were performed in triplicate and statistical analyses were performed by two-tailed Student t test using the SPSS software package version 12.0. For in vivo study, animals were randomly chosen, and blinded outcome assessment and concealed allocation were used. In vivo treatment effects were evaluated using a one-way analysis of variance (ANOVA), followed by post-hoc test analysis for individual group comparisons. Results from multiple experiments were expressed as the means ± standard deviations (SDs), and differences were considered statistically significant when p < 0.05.

Results
MT triggers ER stress-associated FGF19 upregulation in HNSCC cells
We first determined the cytotoxicity of MT in HNSCC cell lines by treating them with varied doses of MT for 3 days. MT exhibited strong effects on cell viability inhibition and apoptosis induction among HNSCC cells examined (Fig. 1a and b), which was consistent with previous studies reporting MT’s anticancer potency [26, 34, 35]. Compared with HN6 and HN30 cells, HN12 cells were more resistant to MT (Fig. 1a and b). An active form of Caspase 3 (c-Caspase 3) was detected in cancer cells treated with MT (Fig. 1c), which confirmed flow cytometry analysis at the molecular level. Interestingly, c-Caspase 12 was also seen in cancer cells following MT exposure (Fig. 1c), suggesting that MT may ignite the apoptotic pathway through ER stress induction. We then treated cells with 5 mM MT following a time course and subjected them to Western blotting with antibodies against ER stress-responsive proteins. Increased protein levels of ATF6 and IRE-1, coupled with enhanced phosphorylation levels of PERK were seen in cells treated with MT within 12 h (Fig. 1d). While the levels of IRE-1 protein and PERK phosphorylation were increased dramatically following MT treatment, ATF6 protein levels were elevated moderately (Fig. 1d). ER stress has been reported to govern cell survival and death through functionally linking to mitochondria [22, 36]. To determine whether MT-induced ER stress-associated death was mediated by the mitochondrial pathway of apoptosis in HNSCC cells, we assessed the changes in mitochondria-localized Bcl-2 family proteins in the presence or absence of MT. Western blotting analysis revealed an upregulation of BH1–3 pro-apoptotic Bcl-2 protein Bax upon MT treatment, which was accompanied by increased BH3-only Bcl-2 proteins Puma and Noxa (Supplementary Figure S1). As BH3-only Bcl-2 family proteins are effectors of canonical mitochondrial apoptosis, which discharge their pro-apoptotic functions through BH1–3 pro-apoptotic proteins, our findings indicate that ER stress triggered by MT induces HNSCC cell apoptosis via mitochondria-dependent pathway.

Increased PERK phosphorylation prompted us to determine eIF2α-activating ATF4 signaling, as it is commonly regulated by PERK when phosphorylated upon ER stress [37]. The levels of phosphorylated eIF2α were markedly elevated at 2 hours after MT treatment, along with the increase of ATF4 (Fig. 1e). ATF4 is a critical regulator involved in ER stress-induced FGF19 upregulation in HCC cells [7]. As ATF4 was elevated in MT treatment, we determined the FGF19 expression following MT treatment in HNSCC cells. MT led to a significant increase in FGF19 protein levels, concomitant with increased phosphorylation levels of its receptor FGFR4 (Fig. 1f). QRT-PCR further showed MT-induced FGF19 upregulation at the mRNA level (Fig. 1g).

High-dose MT promotes FGF19 upregulation in HNSCC cells via ER stress-induced ATF4 activation
Intriguingly, reduction of MT dose from 5 mM to 0.5 mM did not activate eIF2α-ATF4 axis and altered FGF19 protein levels in all three HNSCC cells (Fig. 2a),
suggesting that only high-dose MT can induce FGF19 upregulation. To understand whether MT signals through its receptors, we first determined the expression levels of MT receptor 1A (MTNR1A). RT-PCR analysis revealed that normal oral keratinocytes expressed MTNR1A, but MTNR1A mRNA was not detected in all cancer cell lines examined in our study (Fig. 2b). This observation suggests that MT activates the eIF2α-ATF4-FGF19 pathway through receptor-independent mechanism. We then developed orthotopic NSG mice and intra-tumorally injected low (0.5 mM) or high dose (5 mM) of MT when HN12-derived xenografts were formed on the mice tongue (Fig. 2c). In accordance with in vitro data, MT at high dose, but not at low dose, enhanced ATF4 protein levels in the isolated xenograft tumors as measured by western blotting and IHC (Fig. 2c and d).

To determine the clinical correlation between serum FGF19 and MT concentrations, we collected blood samples from age-matched healthy people and HNSCC patients. ELISA analysis showed higher levels of serum MT levels, but not serum FGF19 in the blood of HNSCC patients compared with the healthy cohort (Supplementary Figure S2A). Spearman’s rank correlation coefficient analysis demonstrated no good correlation of the serum FGF19 level with MT in the HNSCC patient cohort (Supplementary Figure S2B), suggesting that MT has no significant influence on systemic levels of FGF19 in HNSCC patients. However, IHC data from this cohort rendered that patients with high concentrations of serum MT had significantly higher FGF19 protein levels in tumor tissues than those with low concentrations of serum MT (Fig. 2e). These findings imply that serum
MT is one possible contributing factor to the upregulation of FGF19 in HNSCC.

Next, we depleted ATF4 expression in HN12 cells and measured the FGF19 expression in the presence or absence of 5 mM MT (Fig. 2f). While the addition of MT increased FGF19 levels in the knockdown control cells, no changes in FGF19 levels were detected in either MT treated or non-treated cells when ATF4 was depleted (Fig. 2g). ChIP-qPCR assays clearly showed ATF4 bound to the FGF19 promoter in HN12 cells (Fig. 2h) and increased amount of ATF4 at the FGF19 promoter binding site in the presence of 5 mM MT (Fig. 2i), indicating that MT-induced ER stress promotes ATF4 upregulation, which in turn transcriptionally activates FGF19 in HNSCC cells.
FGF19-FGFR4 signaling axis confines the role of MT in suppressing cell motility via Vimentin upregulation in HNSCC cells

Next, we determined whether MT has an impact on HNSCC cell migration. Wound healing assay showed that while MT repressed wound closure in highly-invasive HN12 cells at 16 h (Fig. 3a), its inhibitory effect was more significant at 0.5 mM compared with 5 mM (Fig. 3a), suggesting that high-dose MT may enhance cell-killing effect but attenuate the role in suppressing cell motility. Intriguingly, elevated Vimentin was seen in cells treated with 5 mM MT, which was accompanied by E-cadherin reduction (Fig. 3b). To examine whether FGF19 was involved in Vimentin upregulation in HNSCC cells, we knocked down the FGF19 gene in HN12 cells. FGF19 knockdown not only repressed Vimentin expression (Fig. 3c) but also abrogated its increase upon high-dose MT exposure and enhanced the inhibitory effect of MT on cell migration (Fig. 3d and f). We then depleted FGFR4 in HN12 cells using the CRISPR/Cas9 system. Three FGFR4 KO clones (#2, #3 and #4) rendered decreased Vimentin protein levels consistently compared with the parental control cells (Fig. 3e). Moreover, knockout of FGFR4 led to a reduction in cell migration and augmented the effect of MT on migration suppression (Fig. 3f). H3B-6527, a highly selective covalent FGFR4 inhibitor, also exhibited a suppressive effect on Vimentin protein levels at 5 μM (Fig. 3g), leading to impaired wound healing capacity in HN12 cells (Fig. 3h). Most importantly, additional H3B-6527 significantly enhanced MT-induced migration inhibition (Fig. 3h), which was consistent with the results from FGF19 or FGFR4 gene depletion. These findings indicate that high-dose MT only has limited effect on suppressing cell motility in HNSCC cells due to the induction of FGF19-FGFR4-Vimentin signaling.

**FGF19-FGFR4 signaling axis switches the role of MT in cell motility when epithelial HNSCC cells were long exposed to high-dose MT**

Unlike HN12 cells, HN30 cells are epithelial and non-invasive HNSCC cells. To better understand the role of
FGF19 in MT treatment, we used HN30 cells to develop MT-LE cells by maintaining them in medium containing 5 mM MT for more than 10 generations. We first assessed the apoptotic status of MT-LE cells by examining c-Caspase 3 levels. The cleaved Caspase 3 was observed in HN30 cells after short exposure of MT (MT-SE) but it was not detected in MT-LE cells (Supplemental Figure S4), suggesting that HNSCC cells may acquire resistance to MT-induced apoptosis after a long exposure. Strikingly, elevated FGF19 coupling with ATF4 and Vimentin were observed in MT-LE cells compared with its parental cells and MT-SE cells that were only exposed to 5 mM MT for 12 h (Fig. 4a). ChIP-qPCR assays further showed enriched ATF4 bound on the FGF19 promoter in MT-LE cells than that in either its parental or MT-SE cells (Fig. 4b). Morphologically, parental HN30 cells were characterized as “tight colonies” [38] with typical epithelial shape (Fig. 4c). Short-term exposure to MT did not change HN30 morphology (data not shown), but MT-LE cells appeared spindle-shaped and made few contacts with adjacent cells (Fig. 4c), suggesting EMT in HNSCC cells after long-term exposure to high-dose MT. A clear increase in scratch-wound healing capability was noted in MT-LE cells compared with its parental cells (Fig. 4d), which prompted us to further study their invasion abilities in a 3D scaffold. While the parental cells growing in the SeedEZ 3D ring only displayed short-distance invasion, MT-LE cells efficiently invaded at long-distance (Fig. 4e), suggesting that HNSCC cells may gain metastatic potential when long exposed to high-dose MT.

To explore how FGF19 contributes to the switch of MT’s role in cell motility, we overexpressed FGF19 in HN30 cells, which showed increased Vimentin levels along with acquired migration capacity compared with the control cells (Supplementary Figure S3). We then knocked down the FGF19 gene in MT-LE and its parental HN30 cells. HN30 cells showed no effect to FGF19 knockdown on cell migration (Fig. 4f), which may be due to the nature of low FGF19 expression levels. In contrast, FGF19 loss significantly diminished the migration potential of MT-LE cells and was associated with

Fig. 4 FGF19-FGFR4 signaling axis switches the role of MT in cell motility upon long-term exposure to high-dose MT. a Increased levels of ATF4, FGF19, and Vimentin in MT-SE and MT-LE HN30 cells. b The increased ATF4 amount on the FGF19 gene promoter in MT-LE HN30 cells than that in parental HN30 cells determined by ChIP-qPCR. c The morphological changes between MT-LE and its parental HN30 cells photographed under an inverted phase-contrast microscopy. d Comparison of migration capacity between MT-LE and its parental HN30 cells by wound healing assays. e Comparison of ex vivo invasion potential between MT-LE and its parental HN30 cells by SeedEZ™ 3D rings. f, g The effect of FGF19 knockdown (shFGF19) on cell migration (f) and Vimentin protein levels (g) in MT-LE HN30 cells. h, i The effect of H3B-6527 on cell migration (h) and Vimentin protein levels (i) in MT-LE HN30 cells. In (d, e, f, h) representative images and quantitative data from three independent experiments are shown in the left and right panels, respectively. MT-SE, HN30 cells under 12-h exposure of MT; MT-LE, HN30 cells under long-term exposure of MT. *p < 0.05; **p < 0.01
increased Vimentin (Fig. 4f and g). Consistently, inactivation of FGFR4 by its inhibitor H3B-6527 repressed Vimentin protein expression in MT-LE cells, leading to a reduction in cell migration (Fig. 4h and i).

**Blockade of FGF19/FGFR4 signaling axis attenuates the cervical lymph node metastases (LNMets) of MT-LE HNSCC cells**

Luciferase-containing MT-LE and its parental HN30 cells with or without FGF19 knockdown were generated and individually injected into the anterior tongue of NSG mice (n = 5/group). There were no noticeable changes in tumor growth in mice receiving FGF19 knockdown or its knockdown control cells (Fig. 5a) after a four-week inoculation. A marked increase in tumor growth was observed in mice implanted with knockdown control MT-LE cells (Fig. 5a and b). FGF19 knockdown suppressed xenograft tumor growth derived from knockdown control MT-LE cells (Fig. 5a and b). Moreover, no LNMets were observed in mice that were implanted with knockdown control parental cells after a four-week inoculation, but knockdown control MT-LE cells developed LNMets in mice as illustrated by the bioluminescence signal in mice lymph nodes (Fig. 5c). Most importantly, the bioluminescence was only detected in three out of five mice implanted with FGF19 knockdown MT-LE cells, and the signal intensity was much lower compared with that in mice receiving knockdown control MT-LE cells (Fig. 5c). In addition, higher levels of Vimentin were consistently seen in tumor tissues derived from knockdown control MT-LE cells compared with knockdown control parental cells (Fig. 5d), which were dramatically suppressed in xenograft tumors when FGF19 was depleted (Fig. 5d).

Tumor burden was also decreased in tumor-bearing mice treated with H3B-6527 (Fig. 6a and b). No tumor cells derived from the parental HN30 cells metastasized into lymph nodes as no bioluminescence was there (Fig. 6c). However, strong bioluminescence signals were detected from lymph nodes in mice that were implanted with MT-LE cells (Fig. 6c), supporting the notion that HNSCC cells become more aggressive when they are exposed to high-dose MT for a long time. After H3B-6527 treatment, only two mice (40%) implanted with MT-LE cells developed tiny secondary tumors in mice lymph nodes at the endpoint (Fig. 6c). H&E staining showed no
Inactivation of FGFR4 blocks the LN Mets of MT-LE HNSCC cells in orthotopic mice of tongue tumors. a, b Bioluminescence images of tongue tumors (a) and tongue tumor weight (b) in mice receiving vehicle or H3B-6527 after 2 weeks of intratumoral treatment. c Bioluminescence images of tumor dissemination in lymph nodes in mice receiving vehicle or H3B-6527 after a two-week intratumoral treatment. d Histology of major organs at the endpoint of each treatment. e The protein levels of Vimentin in tumor xenografts from mice treated with or without H3B-6527 determined by IHC. In (a, c, d, e), representative images and quantitative data are shown in the left and right panels, respectively. *p < 0.05; **p < 0.01.
detectable morphologic changes in the major organs (Fig. 6d) among all four groups, suggesting H3B-6527 has no or litter systemic toxicity. IHC analysis further indicated that increased Vimentin in MT-LE cell-derived tumors was dramatically attenuated by H3B-6527 (Fig. 6e). Taken together, these observations suggest that blockade of FGF19-FGFR4 signaling has the potential to reverse the aggressiveness developed along with long exposure of high-dose MT.

Discussion

HNSCC remains a challenging clinical problem because of the persisting high rate of local and distant failure [39]. LNMets are the most important prognostic factor for patients with malignant tumors of epithelial origin, which portend worse survival of HNSCC patients [40]. However, the mechanisms by which malignant tumors evade the primary tumor site and metastasize to regional lymph nodes remain elusive. Here we report that high-dose MT not only induces ER stress-associated apoptosis in HNSCC cells but also promotes FGF19/FGFR4 signaling via activating ER stress-responsive PERK-eIF2α-ATF4 pathway (Fig. 7). Most importantly, upregulation of FGF19/FGFR4 axis confines the role of MT in suppressing metastasis and even triggers the switch of its function from anti-metastasis to metastasis promotion (Fig. 7).

In some cases, MT can directly stimulate mitochondrial differentiation and mitochondria-based apoptosis [41], while it appears that MT triggers mitochondria-based apoptosis in HNSCC cells under ER stress. Besides the appearance of c-Caspase 3 and c-Caspase 12, the expression levels of pro-apoptotic Bcl-2 family proteins, including Puma, Noxa and Bax, were also observed increase in MT-treated HNSCC cells. ATF4 regulates the cellular response to ER stress and its involvement in the ER stress-mediated upregulation of pro-apoptotic Bcl-2 family proteins has been well studied [36, 42]. We have demonstrated that MT results in the upregulation of ATF4 following ER stress in HNSCC cells, thus, ATF4-dependent transactivation of pro-apoptotic Bcl-2 family members is implicated in MT-induced ER stress-associated apoptosis.

While serum FGF19 is considered as a potential novel biomarker for HCC [43], it appears that serum FGF19 may not help improve the prognosis in HNSCC patients as there is no statistical difference in serum FGF19 between patients and healthy controls. In our prospective study of patients with HNSCC, we found higher levels of serum MT associated with increased FGF19 levels in tumor tissues, but these patients did not show a good correlation between the concentrations of serum MT and FGF19, suggesting MT is most likely involved in FGF19 upregulation in tumor cells. These findings may only reflect the cohort of HNSCC patients that we enrolled, and there is a possibility that many other factors related to MT levels in patients’ blood have not been fully considered. However, we at least provide a principle of concept that the determination of serum MT levels may enable to predict the levels of FGF19 in head and neck tumor tissues, which would be beneficial for FGFR4-based therapeutics.

HN30 and HN31 are the two cell lines respectively derived from primary lesions in the base of pharynx and lymph node metastatic lesions belonging to the same HNSCC patient [44]. Our previous study provides evidence that the highly invasive HN31 cells express higher levels of FGF19 than do the less invasive

---

**Fig. 7** Schematic representation of MT-mediated FGF19 signaling in HNSCC cells. High-dose MT has the potential to upregulate FGF19 gene expression through activating ER stress-responsive PERK-eIF2a-ATF4 signaling in HNSCC cells. Increased FGF19 is secreted and then recruited back to cells by its specific receptor FGFR4 and further activates Vimentin signaling, which in turn confines the role of MT in anti-metastasis.
HN30 cells [25], suggesting the possible correlation between FGF19 expression levels and invasiveness of HNSCC cells. In this study, the observation that MT-LE HN30 cells progress to highly invasive cancer cells with elevated FGF19 expression prompted us to determine the specific role of FGF19 in cell aggressiveness associated with MT treatment. We found significantly increased FGF19 expression levels in MT-LE HN30 cells and depleting it in these cells suppressed cell motility. Crucially, loss of FGF19 attenuated metastatic potential of tongue tumors that were derived from MT-LE HN30 cells. These findings suggest that MT-induced increase of FGF19 gene expression shapes the role of MT in metastasis.

Intriguingly, the present study reveals that only high doses of MT can effectively activate ER stress-associated ATF4-dependent FGF19 upregulation in HNSCC cells, which redirects cell motility promotion to FGFR4-Vimentin signaling. This may partially explain why high-dose MT only has a limited effect on suppressing cell migration. It is noteworthy that epithelial HNSCC cells gain the capability to drive metastatic progression in an FGF19-dependent manner and develop malignancy when they are long exposed to high-dose MT. This data implicates that treatment with high-dose MT may change the epithelial plasticity and enable epithelial carcinoma cells to metastasis via FGF19 signaling. We previously uncovered that FGFR4 promotes EMT in HCC cells by activating GSK3β/β-catenin signaling [6]. The human Vimentin promoter was found to be upregulated by β-catenin/TCF-4 pathway or other mechanisms [45]. Nevertheless, considering the regulatory role of β-catenin may vary with the cellular background, in HNSCC cells, it remains undiscovered whether β-catenin is required for the regulation of Vimentin by FGFR4. Further exploration of the underlying mechanism is warranted, especially under the influence of high-dose MT. Besides the link between FGF19 expression and MT efficacy, the new knowledge regarding the involvement of FGF19 in the process of LNMets should enable improvements in prognostic and possibly therapeutic approaches to the management of malignant HNSCC.

As targeting FGFR4 becomes increasingly more feasible than directly targeting FGF19, highly selective FGFR4 inhibitors have become commercially available for preclinical tests [46–49], providing new approaches to treat a subgroup of FGF19-driven cancers. H3B-6527 has shown FGFR4 pathway modulation in Hep3B cells through the direct covalent binding to the ATP pocket of FGFR4 [47]. Although the pharmacodynamics and therapeutic efficacy of H3B-6527 have been evaluated in different mice models bearing HCC [47], none has shed light on other types of cancer. In the present study, we did not observe the potency of H3B-6527 in preventing the development of HN30 cell-derived tumors in mice, which may be due to the native low FGF19 expression in HN30 cells. However, tumor growth and aggressiveness in these tumors derived from MT-LE HN30 cells can be effectively suppressed by H3B-6527. This was attribute to the blockade of hyperactivated FGF19/FGFR4 signaling in MT-LE cells. Our data potentially indicates that FGF19 elevation is a strong predictor of H3B-6527 response in HNSCC cells.

In a xenograft model of HCC, H3B-6527 was administered orally either on a once-daily or twice-daily schedule [47]. We applied H3B-6527 at a high dose of 300 mg/kg once daily to orthotopic xenograft mice, but oral administration did not lead to tumor remission before tumor-bearing mice reached a moribund state. Therefore, to overcome this challenge, we switched to intratumoral treatment. In principle, intratumoral injections can be considered for any tumor where the primary lesion or its metastases are accessible [50], though there is only limited clinical use of non-systemic intratumoral therapy for cancers. In the present study, we demonstrate that direct injection into the tongue tumor not only reduces systemic exposure to avoid off-target toxicities but also decreases the amounts of H3B-6527 with stronger antitumor activity, which may provide a preclinical foundation for future opportunities for safer, more effective, and clinically practical non-systemic therapy.

Conclusions
To our knowledge, this study is the first to interrogate the multifaceted role of MT in metastasis. Our findings provide novel mechanistic insight into tumor aggressiveness that is associated with MT-mediated upregulation of FGF19/FGFR4 signaling axis, suggesting that inactivating this molecular node may help actualize the promise of MT supplements in cancers.

Abbreviations
3D: Three-dimensional; ATF4: Activating transcription factor 4; CLD: Chronic liver disease; ChIP-qPCR: Chromatin immunoprecipitation qPCR; DMEM: Dulbecco’s modified Eagle’s medium; eIF2α: Eukaryotic initiation factor 2 alpha; EMT: Epithelial-mesenchymal transition; ER: Endoplasmic reticulum; FGFs: Fibroblast growth factors; HCC: Hepatocellular carcinoma; H&E: Hematoxylin-and-eosin; HNSCC: Head and neck squamous cell carcinoma; IACUC: Institutional Animal Care and Use Committee; IHC: Immunohistochemistry; KO: Knockout; LNMets: Lymph node metastases; MT: Melatonin; MT-LE: Cells with melatonin long-term exposure; MT-SE: Cells with melatonin short-term exposure; qRT-PCR: Quantitative RT-PCR; ROS: Reactive oxygen species; SDs: Standard deviations; sgRNAs: Single-guide RNAs; shRNA: Short hairpin RNA; siRNA: Small interfering RNA.
Acknowledgments

We would like to thank the other team members for their technical assistance. We are also grateful to Dr. Honglin Li for antibody sharing.

Authors’ contributions

L.L., Y.X., N.P-O., R.L., and C.J. performed research and analyzed results; C.S. discussed results and edited the paper; Y.T. designed research; wrote the paper and supervised the study.

Funding

This work was supported in part by NIH/NCICR (R01DE028331 and R03DE028837) and CURS Summer Scholars award to Y.T. and NSFC (20202BABL206066) to Y.X.

Availability of data and materials

All data generated or analyzed during this study are included in this published article [and its supplementary information files].

Declarations

Ethics approval and consent to participate

Studies involving human samples were reviewed and approved by the Ethics Committee of Nanchang University. All patients provided written informed consent. Studies involving animals were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Augusta University.

Consent for publication

All authors read and approved the final manuscript.

Competing interests

The authors declare no competing financial interests.

Author details

1Department of Oral Biology and Diagnostic Sciences, Dental College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912, USA.
2Present address: Department of Otolaryngology Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
3Department of Pediatrics, Emory Children’s Center, Emory University, Atlanta, GA, USA.
4Georgina Cancer Center, Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
5Department of Medical Laboratory, Imaging and Radiologic Sciences, College of Allied Health, Augusta University, Augusta, GA, USA.

Received: 30 November 2020 Accepted: 21 February 2021

Published online: 10 March 2021

References

1. Lang L, Teng Y. Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies. Cells. 2019B(8):131.
2. Degirolamo C, Sabbà C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGFR19, FGFR21 and FGFR23. Nat Rev Drug Discov. 2016B(15):151–69.
3. Walters JR. Bile acid diarhoea and FGFR19: new views on diagnosis, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2014B(11):7426–34.
4. Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L. Identification of a therapeutic strategy targeting amplified FGFR19 in liver cancer by Oncogenicomic screening. Cancer Cell. 2011B(19):347–58.
5. Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7a-hydroxylase gene expression. Hepatology. 2009B(49):297–305.
6. Zhao H, Lv F, Liang G, Huang X, Wu G, Zhang W, Yu L, Shi L, Teng Y. FGFR19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3B/catenin signaling cascade via FGFR4 activation. Oncotarget. 2016B(12):13575–86.
7. Teng Y, Zhao H, Gao L, Zhang W, Shull AY, Shay C. FGFR19 protects hepatocellular carcinoma cells against endoplasmic reticulum stress via activation of FGFR4–GSK3B–βcat2 signaling. Cancer Res. 2017B(77):26215–25.
8. Gao L, Wang X, Tang Y, Huang S, Hu C, A, Teng Y. FGFR19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res. 2017B(36):1–10.
9. Mauriz JL, Collados PS, Veneroso C, Reiter RJ, González-Gallego J. A review of the molecular aspects of melanotin’s anti-inflammatory actions: recent insights and new perspectives. J Pineal Res. 2013B(54):1–14.
10. Manchester LC, Coto-Montes A, Boga JA, Andersen LPH, Zhou Z, Galano A, Vriend J, Tan DX, Reiter RJ. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015B(59):403–19.
11. Capote-Moreno A, Ramos E, Egea J, López-Muñoz F, Gil-Martin E, Romero A. Potential of melatonin as adjuvant therapy of oral cancer in the era of epigenomics. Cancers (Basel). 2019B(11):1712.
12. Claussbrat B, Leston J. Melatonin: physiological effects in humans. Neurochirurgie. 2015B(61):3–77–84.
13. Su SC, Hisheh MI, Yang WE, Chung WH, Reiter RJ, Yang SF. Cancer metastasis: novel mechanisms of inhibition by melatonin. J Pineal Res. 2017B(62):1–12.
14. Boga JA, Caballero B, Potes Y, Perez-Martinez Z, Reiter RJ, Vega-Naredo J, Coto-Montes A. Therapeutic potential of melatonin related to its role as an autophagy regulator: a review. J Pineal Res. 2019B(66):e12534.
15. Talib WH. Melatonin and cancer hallmarks. Molecules. 2018B(23):315B.
16. Farhood B, Goradel NH, Mortezaee K, Khandarhanhi N, Nafaji M, Sahaebkar A. Melatonin and cancer: from the promotion of genomic stability to use in cancer treatment. J Cell Physiol. 2019B(234):5613–27.
17. Gu H, Shen Q, Mei D, Yang Y, Wei R, Ni M. Melatonin inhibits TE-1 esophageal cancer cells metastasis by suppressing the NF-κB signaling pathway and decreasing MMP-9. Ann Clin Lab Sci. 2020B(50):65–72.
18. Fernandez-Gil B, Guerra-Llibero A, Shen YQ, Florido J, Martinez-Ruiz L, García-López S, Adán C, Rodríguez-Santana C, Acuña-Castroviejo D, Quiñones-Hinojosa A. Melatonin enhances cisplatin and radiation cytotoxicity in head and neck squamous cell carcinoma by stimulating mitochondrial ROS generation, apoptosis, and autophagy. Oxidative Med Cell Longev. 2019B:178128.
19. Shen YQ, Guerra-Llibero A, Fernandez-Gil B, Florido J, García-López S, Martinez-Ruiz L, Mendivil-Perez M, Soto-Mercado V, Acuña-Castroviejo D, Ortega-Arellano H. Combination of melatonin and rapamycin for head and neck cancer therapy: suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation. J Pineal Res. 2018B(64):31:1e12461.
20. Sung ES, Kim JY, Ahn YT, Lee IW, Choi SW, Jang HB, Lee JC, An WG. Melatonin exerts anticancer effects in human tongue squamous cell carcinoma cells by promoting autophagy. Anticancer Res. 2020B(40):1:629–303.
21. Fernández A, Ordôñez R, Reiter RJ, González-Gallego J, Mauriz JL. Melatonin and endoplasmic reticulum stress: relation to autophagy and apoptosis. J Pineal Res. 2015B(59):3–292–307.
22. Cai Y, Li J, Zhang Z, Chen J, Zhu Y, Li R, Chen J, Gao L, Liu R, Teng Y. Zbtb38 is a novel target for spinal cord injury. Oncotarget. 2017B(8):30456.
23. Li Y, Li S, Zhou Y, Meng X, Zhang J-J, Xu DP, Li HB. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017B(8):24:39806.
24. Jung B, Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res. 2006B(66):9789–93.
25. Gao L, Lang L, Zhao X, Shay C, Shull AY, Teng Y. FGFR19 amplification reveals an oncogenic dependency upon autocrine FGFR19/FGFR4 signaling in head and neck squamous cell carcinoma. Oncogene. 2019B(12):3394–404.
26. Lang L, Shay C, Zhao X, Xiong Y, Wang X, Teng Y. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma. J Hematol Oncol. 2019B(12):11:132.
27. Gao L, Zhao X, Lang L, Shay C, Yeudall WA, Teng Y. Autophagy blockade sensitizes human head and neck squamous cell carcinoma towards CT2997
through enhancing excessively high reactive oxygen species-induced apoptosis. J Mol Med. 2018;96(9):929–38.
28. Farwell DG, Shera KA, Koop JJ, Bonnet GA, Matthews CP, Reuther GW, Collrera MD, McDougall JK, Klingelfizet AJ. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. Am J Pathol. 2000;156(3):1537–47.
29. Teng Y, Cai Y, Pi W, Gao L, Shay C. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity. J Hematol Oncol. 2017;10(1):1–10.
30. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281–308.
31. Xiong Y, He L, Shay C, Lang L, Lovelice J, Yu J, Chemmalakuzhy R, Jiang H, Liu M, Teng Y. N-linked glycosylation of protein A, N-linked glycosylation in human non-small-cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):122.
32. Lang L, Lam T, Chen A, Jensen C, Duncan L, Kong FC, Kurago ZB, Shay C, Teng Y. Circumventing AKT-Associated Radioreistance in Oral Cancer by Novel Nanoparticle-Encapsulated Capvasept. Cells. 2020;9(3):533.
33. Lang L, Shay C, Xiong Y, Thakkar P, Chemmalakuzhy R, Wang X, Teng Y. Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib. J Hematol Oncol. 2018;11(1):85–97.
34. Zhao X, Xu F, Domínguez NP, Xiong Y, Xiong Z, Peng H, Shay C, Teng Y. FGFR4 provides the conduit to facilitate FGFR19 signaling in breast cancer progression. Mol Carcinog. 2018;57(11):1616–25.
35. Crowe AR, Yue W. Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: An integrated protocol. Bio Protoc. 2019;9(24):e3465.
36. Malhotra JD, Kaufman RJ. ER stress and its functional link to mitochondria: role in cell survival and death. Cold Spring Harb Perspect Biol. 2011;3(9):a004424.
37. Prieto-Dominguez N, Ordóñez R, Fernández A, Méndez-Blanco C, Baules A, García-Ruiz C, Fernández-Checa JC, Maurus JL, González-Gallego J. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J Pineal Res. 2016;61(3):396–407.
38. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res. 2011;17(23):248–64.
39. Chow LQ. Head and neck cancer. N Engl J Med. 2020;382(1):60–72.
40. Huang L, David O, Cabay RJ, Valyi-Nagy K, Macias V, Zhong R, Wenig B, Hao MH, Bailey S, Wu J. H3B-6527 is a potent and selective inhibitor of histone acetylation-independent blockade of the EGFR-Arf1 axis. J Exp Clin Cancer Res. 2019;38(1):1
41. Prieto-Dominguez N, Ordóñez R, Fernández A, Méndez-Blanco C, Baules A, García-Ruiz C, Fernández-Checa JC, Maurus JL, González-Gallego J. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J Pineal Res. 2016;61(3):396–407.
42. Farwell DG, Shera KA, Koop JJ, Bonnet GA, Matthews CP, Reuther GW, Collrera MD, McDougall JK, Klingelfizet AJ. Genetic and epigenetic changes in human epithelial cells immortalized by telomerase. Am J Pathol. 2000;156(3):1537–47.
43. Lang L, Lam T, Chen A, Jensen C, Duncan L, Kong FC, Kurago ZB, Shay C, Teng Y. Circumventing AKT-Associated Radioreistance in Oral Cancer by Novel Nanoparticle-Encapsulated Capvasept. Cells. 2020;9(3):533.
44. Lang L, Shay C, Xiong Y, Thakkar P, Chemmalakuzhy R, Wang X, Teng Y. Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib. J Hematol Oncol. 2018;11(1):85–97.
45. Zhao X, Xu F, Domínguez NP, Xiong Y, Xiong Z, Peng H, Shay C, Teng Y. FGFR4 provides the conduit to facilitate FGFR19 signaling in breast cancer progression. Mol Carcinog. 2018;57(11):1616–25.
46. Crowe AR, Yue W. Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: An integrated protocol. Bio Protoc. 2019;9(24):e3465.
47. Malhotra JD, Kaufman RJ. ER stress and its functional link to mitochondria: role in cell survival and death. Cold Spring Harb Perspect Biol. 2011;3(9):a004424.
48. Prieto-Dominguez N, Ordóñez R, Fernández A, Méndez-Blanco C, Baules A, García-Ruiz C, Fernández-Checa JC, Maurus JL, González-Gallego J. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy. J Pineal Res. 2016;61(3):396–407.
49. Hatlen MA, Schmidt-Kittler O, Sherzaheyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Broojmans N. Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma. Cancer Discov. 2019;9(12):1686–95.
50. Goldberg EP, Hadia AR, Almond BA, Marotta JS. Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol. 2002;54(2):159–80.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.